Search Patents
  • COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19
    Publication number: 20230242626
    Abstract: The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.
    Type: Application
    Filed: November 4, 2022
    Publication date: August 3, 2023
    Inventors: Albert SCHMELZER, Sajal PATEL, Annette MEDINA, Austin GALLEGOS
  • MICROBIAL REDUCTION COATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230151224
    Abstract: In an embodiment, the present disclosure pertains to a method of coating a substrate to impart antiviral and water resistance to the substrate. In general, the method includes obtaining a substrate and applying a coating composition to the substrate. In some embodiments, the coating composition imparts antiviral and water resistance properties to the substrate. In some embodiments, the coating composition has an antiviral method of action against a virus by causing damage to at least one of a capsid of the virus, an outer envelope of a protein layer of the virus, a spike protein of the virus, a cellular membrane of the virus, or combinations thereof.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 18, 2023
    Applicant: UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Seamus Curran, Kang-Shyang Liao, Surendra Maharjan, Alexander Wang, Eileen Mellon
  • SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding
    Patent number: 11054429
    Abstract: A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: July 6, 2021
    Assignee: National University of Singapore
    Inventor: Linfa Wang
  • CORONAVIRUS VACCINES AND USES THEREOF
    Publication number: 20230015616
    Abstract: This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
    Type: Application
    Filed: November 30, 2020
    Publication date: January 19, 2023
    Inventors: Bill Biliang ZHANG, Man LI, Lin MA, Jian WEN, Hong ZHANG, Huiling ZHONG
  • POLYNUCLEOTIDES ENCODING SARS-COV-2 ANTIGENS AND USE THEREOF IN THE MEDICAL FIELD AS VACCINES
    Publication number: 20230285540
    Abstract: The present invention relates to polynucleotides encoding antigens of the SARS-CoV-2 coronavirus spike protein and use thereof in the medical field as vaccines for the prevention and treatment of COVID-19 infection.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 14, 2023
    Inventors: Luigi AURISICCHIO, Emanuele MARRA, Giuseppe ROSCILLI, Fabio PALOMBO, Mariano MAFFEI, Alessia MUZI
  • COMPOSITIONS COMPRISING COMPLEXES DISPLAYING ANTIGENS AND METHODS OF USING THE COMPOSITIONS
    Publication number: 20230321217
    Abstract: A nanoparticle that displays a coronavirus spike protein or a portion thereof on its surface, and methods of making and using the nanoparticle, are provided.
    Type: Application
    Filed: September 28, 2022
    Publication date: October 12, 2023
    Inventors: Yoshihiro Kawaoka, Peter J. Halfmann, Ravi Kane, Steven J. Frey, Gabriele Neumann, Shiho Chiba, Ana Luisa Stringari de Castro, Kathryn E. Loeffler
  • IDENTIFICATION OF BIOMIMETIC VIRAL PEPTIDES AND USES THEREOF
    Publication number: 20230242592
    Abstract: Disclosed are small peptides derived from the binding interface of each of SARS-CoV-2 spike protein and ACE2 receptor, compositions comprising the same, and prophylactic and therapeutic uses of the peptides and the compositions. Also disclosed is a novel protocol of identifying, designing, and modifying the small peptides based on computer simulation.
    Type: Application
    Filed: August 24, 2022
    Publication date: August 3, 2023
    Inventors: Andre WATSON, Alexander Izvorski
  • VARIANT STRAIN-BASED CORONAVIRUS VACCINES
    Publication number: 20240139309
    Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 2, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamiltion Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
  • ANTIBODIES FOR CORONAVIRUS AND USES THEREOF
    Publication number: 20230250157
    Abstract: Disclosed herein include antibodies or fragments thereof having specificity to a sarbecovirus spike protein receptor binding domain. Also provided are compositions, methods, and kits for isolating and using said antibodies or fragments thereof for preventing or treating, for example a coronavirus infection.
    Type: Application
    Filed: December 1, 2022
    Publication date: August 10, 2023
    Inventors: Pamela J. Bjorkman, Alexander A. Cohen, Chengcheng Fan, John C. Williams, Miso Park
  • CORONAVIRUSES EPITOPE-BASED VACCINES
    Publication number: 20200308232
    Abstract: Provided are polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. Further provided are compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 1, 2020
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Jonathan GERSHONI, Natalia T. FREUND
  • COVID-19 ANTIBODIES AND USES THEREOF
    Publication number: 20230357364
    Abstract: The present application is directed to recombinant monoclonal antibodies, or antigen fragments thereof that bind a Spike protein of SARS-CoV-2. Methods of using the antibodies to treat or prevent SARS-CoV-2 (COVID-19) are also disclosed.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 9, 2023
    Inventors: Devin Sok, Joseph Jardine, Elise Landais, Dennis Burton, Tom Rogers, Fangzhu Zhao, Deli Huang
  • NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION
    Publication number: 20220135702
    Abstract: An embodiment provides a method for preventing the transmission of Covid-19, including: preparing a composition comprising an ACE2 monoclonal antibody, a Neuropilin-1 antibody, an antibody to the spike protein of Sars-CoV-2, a vegetable oil, and a saline solution; and spraying the composition in a nasal cavity of a patient. Other aspects are described and claimed.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventor: Mitchell S. Felder
  • Compositions and Methods for Inducing an Immune Response
    Publication number: 20230285532
    Abstract: The invention relates to a composition comprising a viral vector, the viral vector comprising nucleic acid having a polynucleotide sequence encoding the spike protein from the coronavirus SARS-CoV2, characterised in that said viral vector is an adenovirus based vector. The invention also relates to uses of such a composition and methods of treatment.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 14, 2023
    Inventors: Sarah C. GILBERT, Teresa LAMBE, Sarah SEBASTIAN
  • Hybrid alphavirus-SARS-CoV-2 particle and methodology of making and using same
    Patent number: 11473064
    Abstract: Timely development of vaccines and antiviral drugs is critical to control the COVID-19 pandemic. Current methods for quantifying vaccine-induced neutralizing antibodies involve the use of pseudoviruses, such as the SARS-CoV-2 spike protein (S) pseudotyped lentivirus. However, these pseudoviruses contain structural proteins foreign to SARS-CoV-2, and require days to infect and express reporter genes. Here, the present application discloses composition and methodology for making and using a new hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) particle for rapid and accurate quantification of neutralization antibodies and viral variants.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: October 18, 2022
    Assignee: George Mason Research Foundation, Inc.
    Inventors: Brian Hetrick, Yuntao Wu
  • Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
    Patent number: 7629443
    Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: December 8, 2009
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Yuxian He
  • SARS-COV2 SPIKE PROTEIN BINDING PEPTIDES
    Publication number: 20230152316
    Abstract: The disclosure provides peptides that are useful for the prevention of infection of coronaviruses, especially SARS-CoV-2. Also described is a method reducing probability of viral infection in a human subject, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: Bradley L. Pentelute, Genwei Zhang, Sebastian Pomplun, Alexander R. Loftis, Andrei Loas
  • DEVELOPMENT OF AN EDIBLE VACCINE
    Publication number: 20220054628
    Abstract: Plant-based, edible vaccines are provided. The vaccines are or are made from plants that are genetically engineered to express antigens of disease-causing microbes, for example, antigens of the MERS-CoV virus, such as the S1 subunit of the spike protein.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 24, 2022
    Inventors: Sayed Sartaj SOHRAB, Esam Ibraheem Ahmed ASHAR, Sherif Aly Abdelkhalek ELKAFRAWY, Ayman Talaat Abbas Abdelhadi, Edward P. RYBICKI, Emmanuel Aubrey MARGOLIN
  • Coronaviruses epitope-based vaccines
    Patent number: 10676511
    Abstract: Provided are polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. Further provided are compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: June 9, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Jonathan Gershoni, Natalia T. Freund
  • CORONAVIRUSES EPITOPE-BASED VACCINES
    Publication number: 20210253645
    Abstract: The present invention provides polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. The invention further provides compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 19, 2021
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Jonathan GERSHONI, Natalia T. FREUND
  • COMBINED USE OF NANOBODY, CYCLODEXTRIN AND QUERCETIN FOR PROTECTION FROM ENVELOPED VIRUSES
    Publication number: 20230357329
    Abstract: Disclosed are engineered nanobodies against different target antigens such as the spike protein of the SARS-CoV-2 virus and or to the ACE2 receptor at the host cell surface, binds to the virus or the ACE2 receptor at the host cell plasma membrane, preventing entry of the SARS-CoV-2 virus.
    Type: Application
    Filed: July 17, 2023
    Publication date: November 9, 2023
    Applicant: VIRON, INC.
    Inventor: Bhanu Pratap Jena
Narrow Results

Filter by US Classification